Mercedes Brunet
Research group
- Steatohepatitis and liver transplantation Accredited researcher (R3A)
Featured publications
-
Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients
Authors: Millan, Olga; Ruiz, Pablo; Orts, Lara; Ferre, Paula; Crespo, Gonzalo; Santana, Miguel; Fortuna, Virginia; Quintairos, Luis; Navasa, Miguel; Brunet, Merce;.Reference: Frontiers In Immunology 2019. -
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Authors: Brunet M; Van Gelder T; Åsberg A; Haufroid V; Hesselink D; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard J; Barten M; Budde K; Colom H; Dieterlen M; Elens L; Johnson-Davis K; Kunicki P; Macphee I; Masuda S; Mathew B; Millán O; Mizuno T; Moes D; Monchaud C; Noceti O; Pawinski T; Picard N; Van Schaik R; Sommerer C; Vethe N; De Winter B; Christians U; Bergan S.Reference: Therapeutic Drug Monitoring 2019. -
Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
Authors: Mauro E, Crespo G, Montironi C, Londoño MC, Hernández-Gea V, Ruiz P, Sastre L, Lombardo J, Mariño Z, Díaz A, Colmenero J, Rimola A, Garcia-Pagán JC, Brunet M, Forns X, Navasa M .Reference: Hepatology 2018. -
Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
Authors: Pericàs JM, García-de-la-Mària C, Brunet M, Armero Y, García-González J, Casals G, Almela M, Quintana E, Falces C, Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Miró JM, Hospital Clinic Endocarditis Study Group.Reference: Journal Of Antimicrobial Chemotherapy 2017. -
Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.
Authors: Millán O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B, Matz M, Zeier M, Silva I, Guirado L, Brunet M .Reference: British Journal Of Clinical Pharmacology 2017. -
Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation
Authors: Crespo G, Gambato M, Millán O, Casals G, Ruiz P, Londoño MC, Mira A, Forns X, Brunet M, Jiménez W, Navasa M .Reference: Transplant Infectious Disease 2016. -
Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation
Authors: Brunet M; Shipkova M; Van Gelder T; Wieland E; Sommerer C; Budde K; Haufroid V; Christians U; López-Hoyos M; Barten M; Bergan S; Picard N; López O; Marquet P; Hesselink D; Noceti O; Pawinski T; Wallemacq P; Oellerich M.Reference: Therapeutic Drug Monitoring 2016. -
Therapeutic Drug Monitoring of Everolimus: A Consensus Report
Authors: Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, López OM, Masuda S, Seger C, Picard N, Oellerich M, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P .Reference: Therapeutic Drug Monitoring 2016. -
Flow cytometry as platform for biomarker discovery and clinical validation
Authors: Millán O; Brunet M.Reference: General Methods In Biomarker Research And Their Applications 2015. -
Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study
Authors: Millan, O; Rafael-Valdivia, L; San Segundo, D; Boix, F; Castro-Panete, MJ; Lopez-Hoyos, M; Muro, M; Valero-Hervas, D; Rimola, A; Navasa, M; Munoz, P; Miras, M; Andres, A; Guirado, L; Pascual, J; Brunet, M.Reference: Clinical Immunology 2014.
Featured Projects
-
Análisis de la expresión de un panel de miRNAs y Quimiocinas como biomarcadores pronóstico precoces del riesgo de rechazo mediado por células T y subclínico post-trasplante hepático.
Principal investigator: Olga Millán López, Mercedes Brunet SerraDuration: 01/10/2019 - 31/10/2022 -
Evaluación del impacto de la aloreactividad en la evolución del injerto y de la reversibilidad de la fibrosis tras el tratamiento de la hepatítis C post-trasplante hepático.
Principal investigator: Miguel Navasa Anadon, Mercedes Brunet SerraDuration: 01/11/2014 - 30/09/2019 -
Estudio multicéntrico para la validación de los biomarcadores de elección que reflejan la respuesta individual de los pacientes trasplantados de órganos sólidos al tratamiento inmunosupresor.
Principal investigator: Mercedes Brunet SerraCode: PI080300Duration: 01/09/2008 - 30/09/2011 -
Sistema de cromatografía líquida detectores UV-VIS y masas triple cuadrupolo LC/MS/MS.
Principal investigator: Mercedes Brunet SerraCode: 03/3619Duration: 01/09/2004 - 30/09/2007 -
Determinació de l’activitat fosfatasa de la calcineurina en els limfòcits T com a marcador biològic del grau d’immunosuppressió assolit en els pacients tractats amb tacrolimus o ciclosporina
Principal investigator: Mercedes Brunet SerraCode: TV3 810-0Duration: 01/10/2000 - 31/10/2002